Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02761993
Other study ID # ST266-PERIO-201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 2016
Est. completion date October 2017

Study information

Verified date July 2021
Source Noveome Biotherapeutics, formerly Stemnion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether ST266 will reduce pocket depth (PD) as an adjunctive to scaling and root planing (SRP) in subjects with moderate to severe periodontal disease.


Description:

The study is a 9-month, randomized, double-blind, parallel-design study of subjects with existing moderate to severe periodontal disease randomly assigned to one of three groups. The primary endpoint of PD change will be evaluated following 9 months of treatment. Subjects will be followed for 9 months for safety and radiographic evaluations. Subjects who meet inclusion criteria will be randomized to one of three treatment groups. Randomization will be stratified by site and smoker status (never smoked or quit smoking more than two years ago vs. has smoked within the last two years). Randomization will be blocked such that assignment to treatment groups both within sites and within smoker status will be approximately even (1:1:1). Treatment will be initiated after SRP. All subjects will be evaluated at baseline and Days 1, 15, 30, 60, 90, 180, and 270.


Recruitment information / eligibility

Status Completed
Enrollment 151
Est. completion date October 2017
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Provision of signed, written informed consent prior to participation in any study-related procedures. - Good general health as evidenced by medical history. - Between 18 and 85 years of age at time of informed consent signature. - Male or female. - Minimum of 18 teeth, excluding third molars. - Having moderate to severe periodontal disease according to AAP definition (at least 6 teeth =6 mm PD and =3 mm CAL at baseline). - Having >30 percent bleeding sites upon probing. - Willing to abstain from chewing gums and other mouth rinses for the study duration. - Ability and willingness to attend all study visits and comply with all study visits and comply with all study procedures and requirements. - Willingness to abstain from routine dental care. - For women with reproductive potential, willingness to use highly effective contraception (e.g. licensed hormonal contraception, intrauterine device, abstinence, or vasectomy in partner). Exclusion Criteria: - Presence of orthodontic appliances. - A soft or hard tissue tumor of the oral cavity. - Any dental condition that requires immediate treatment, such as carious lesions. - Participation in any other clinical study within 30 days of screening or during the study. - Pregnancy or lactation. If a subject meets this criterion, she may be rescreened for study participation when she no longer meets this criterion. - Antibiotic therapy within the last 30 days. - Chronic use (=3 times/week) of anti-inflammatory medications (e.g., non-steroidal anti inflammatory drugs, steroids). Low-dose aspirin (less than 325 mg daily) is allowed. - Immunocompromised subjects. - Subjects with cancer or a history of cancer within the last 5 years of screening. - Any medical history or any concomitant medication that might affect the assessment of the study treatment or periodontal tissues, such as diabetes, nifedipine, phenytoin (Dilantin), or anticoagulant medications (e.g., warfarin [Coumadin] etc.). - Involvement in the planning or conduct of the study. - History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or interfere with interpretation of the subject's study results. - Previous randomization for treatment in the present study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ST266
1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
Drug:
Saline (0.9% NaCl)
Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).

Locations

Country Name City State
United States University of Alabama at Birmingham School of Dentistry Birmingham Alabama
United States Forsyth Institute Cambridge Massachusetts
United States University of North Carolina at Chapel Hill School of Dentistry Chapel Hill North Carolina
United States Oral Health Research Institute Indianapolis Indiana
United States Columbia University College of Dental Medicine New York New York
United States Stony Brook School of Dental Medicine Stony Brook New York

Sponsors (1)

Lead Sponsor Collaborator
Noveome Biotherapeutics, formerly Stemnion

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Pocket Depth (PD) for Those Pockets = 6 mm at Baseline The primary efficacy endpoint of this study is the change from baseline in the PD at 9 months (Day 270) for those pockets =6 mm at baseline. Baseline; 9 months
Secondary Changes in Clinical Attachment Level (CAL) Change in Clinical Attachment Level (CAL) (the measurement of the position of the soft tissue in relation to the cemento-enamel junction (CEJ) that is a fixed point, using probing depth and the distance from the gingival margin to the CEJ.) from baseline in CAL at 9 months (Day 270) in tooth sites with baseline PD = 6mm. Baseline, 9 months
Secondary Bleeding on Probing (BOP) A secondary efficacy endpoint of this study is change from baseline in BOP at 9 months (Day 270) with BOP for each subject calculated as the percentage of tooth sites in the whole mouth with BOP. Baseline and 9 months
See also
  Status Clinical Trial Phase
Completed NCT02618486 - The Effects of Obesity on Non Surgical Periodontal Therapy N/A
Recruiting NCT01785355 - The Impact Of Periodontal Disease Treatment On The General Health Status In Chronic Haemodialyzed Patients
Completed NCT01639183 - Power Toothbrush Use in Nursing Homes to Eliminate Mouth and Body Inflammation N/A
Completed NCT02935322 - Interaction Between Chlorhexidine and Fluoride Phase 4
Completed NCT00093236 - Impact of Gum Infection on Heart Disease N/A
Completed NCT03444363 - Periodontal Treatment With Diode Laser in the Patients With Diabetes Melitus N/A
Completed NCT03641989 - Correlation Between Oral Health and Systemic Inflammation (COHESION) N/A
Withdrawn NCT02202304 - The Effects of Chlorhexidine/Thymol Varnish on Partial Denture Patient Phase 4
Recruiting NCT01568697 - Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Completed NCT04873505 - Functional Validation of Lactobacillus Containing Oral Tablet N/A
Completed NCT01521260 - Implant Surface Decontamination in Peri-implantitis Treatment N/A
Recruiting NCT00553007 - The Relation Between Periodontal Disease and Metabolic Syndrome N/A
Completed NCT01399034 - Epigenetics, DNA Methylation Patterns and Periodontal Disease N/A
Recruiting NCT00162838 - Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells N/A
Completed NCT00016835 - Treating Periodontal Infection: Effects on Glycemic Phase 2
Completed NCT03540498 - Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum N/A
Completed NCT03775967 - Estimation of Sialic Acid and IL10 Levels in Stage 1 and 2 Periodontitis Patients
Completed NCT02914743 - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes N/A
Completed NCT02894463 - Study Aimed at Detecting Potential Abuse of Nitrous Oxide in Children During Dental Care N/A
Completed NCT02289066 - Impact of Periodontal Disease on Outcomes in Diabetes N/A